Dear Audience, Increasing price and cost pressure, regulatory changes and expiring patents are leading to shrinking margins in the pharmaceutical industry. Almost three in four companies believe their industry is in a strategic crisis, according to the results of the „Pharma’s fight for profitability“ study by Roland Berger Strategy Consultants.
For this reason, 78% of the study participants are of the opinion that pharmaceutical companies must adjust their business models to fit the new market requirements. This includes focusing investments on the high-growth emerging markets, which will make up almost 40% of the global pharmaceutical market by 2016.
This view is shared by many pharmaceutical companies: Almost half of those surveyed are willing to relocate their administration, R&D and sales departments to emerging markets.
In this context, our interview partner Michael Dohrmann will share an overview with us of constellations driven by market type (mature or developing) and lifecycle of the pharma products (established or innovative).
Contact Michael Dohrmann / Kontakt zu Michael Dohrmann: email@example.com